The ARL5B Knockout A-549 Polyclonal Cells product provides a validated, CRISPR/Cas9-mediated gene disruption model for targeted loss-of-function studies of ARL5B in the A-549 human lung epithelial cell background. This polyclonal knockout cell population, generated via CRISPR/Cas9 editing and subsequent selection, enables robust investigation of ARL5B-dependent processes without clonal variability. The polyclonal format preserves population-level heterogeneity, making it suitable for pooled functional screens, drug response profiling, and pathway analyses where bulk cellular behavior is informative. Researchers can rely on this genetically defined tool to dissect the contributions of ARL5B to intracellular trafficking and autophagy regulation in a disease-relevant cellular context.
The host A-549 cell line was originally established from a lung adenocarcinoma of a 58-year-old Caucasian male and exhibits a type II alveolar epithelial phenotype. This widely used model retains key features of non-small cell lung cancer, including KRAS mutation and adherent growth, and is extensively employed to study tumor biology, metastatic progression, and therapeutic resistance. The A-549 background provides a physiologically appropriate setting for exploring how ARL5B dysfunction impacts cancer cell metabolism, lysosomal biology, and stress responses. Its well-characterized signaling networks, particularly the mTOR pathway, offer a defined platform for mechanistic dissection of ARL5B??s role in lung adenocarcinoma.
ARL5B encodes a small GTPase that acts as a molecular switch, cycling between inactive GDP-bound and active GTP-bound states to coordinate lysosome positioning and autophagic flux. Upstream, nutrient availability and mTORC1 regulate ARL5B activity, partly via SBF2/MTMR13, while downstream ARL5B interacts with TBC1D2 and the HOPS complex to modulate Rab7-dependent late endosomal/lysosomal trafficking. This network converges on TFEB, a master transcription factor controlling lysosomal biogenesis and autophagy genes; ARL5B-mediated signals influence TFEB localization and activity. Key pathway components include Rag GTPases, TFEB, and lysosomal proteins, positioning ARL5B at an intersection of nutrient sensing and membrane dynamics.
In A-549 cells, ARL5B knockout offers a powerful system to examine how disruption of lysosome-autophagy signaling affects lung adenocarcinoma phenotypes. Given the well-documented role of autophagy in cancer cell survival, metastasis, and drug resistance, this model is particularly valuable for elucidating mechanisms by which ARL5B-dependent trafficking influences tumor aggressiveness. Studies in this background can reveal context-specific dependencies on ARL5B for mTORC1-TFEB communication, lysosomal adaptation, and metabolic reprogramming, providing insights that may guide therapeutic targeting of the autophagy-lysosome axis in lung cancer.
Typical applications include monitoring autophagic flux via western blotting for LC3-II and p62, assessing lysosomal positioning and morphology through immunofluorescence, and quantifying TFEB target gene expression by RT-qPCR. This model also supports functional assays such as cell migration, invasion, and drug sensitivity profiling to probe ARL5B??s contribution to metastatic potential and chemoresistance. The polyclonal knockout population is suitable for siRNA or small-molecule rescue experiments and high-content screening. For additional information and technical support, please contact Ascent Research.
